STOCK TITAN

Major holder boosts stake as Oncology Institute (TOI) insider buys shares

Filing Impact
(Very High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Oncology Institute, Inc. disclosed that 10% owner Jorey Chernett made three open-market purchases of Common Stock, totaling 398,985 shares, at reported weighted average prices of about $2.92$3.42 per share. Following these transactions, he directly owns 10,251,929 shares. The footnotes explain that each reported price is a weighted average for multiple trades within specified intraday price ranges.

Positive

  • None.

Negative

  • None.

Insights

Large 10% owner adds nearly 400K TOI shares in open market.

10% owner Jorey Chernett bought 398,985 shares of Oncology Institute, Inc. common stock through three open-market purchases, with weighted average prices between about $2.92 and $3.42. After these trades, he holds 10,251,929 shares directly.

All transactions use code P, indicating open-market or private purchases rather than option exercises or administrative movements. The filing shows no remaining derivative positions, so this activity purely increases his common stock exposure.

The footnotes note that each reported price is a weighted average across multiple executions within stated ranges, so actual individual trade prices varied during each day. Future company filings may provide context on how this ownership level compares to total shares outstanding and any subsequent trading activity.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chernett Jorey

(Last) (First) (Middle)
6222 INDIANWOOD TR.

(Street)
BLOOMFIELD HILLS MI 48301

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/13/2026 P 263,000 A $2.92(1) 10,115,944 D
Common Stock 03/16/2026 P 60,985 A $3.29(2) 10,176,929 D
Common Stock 03/17/2026 P 75,000 A $3.42(3) 10,251,929 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.77 to $3.34, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.
2. The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.43, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.
3. The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.39 to $3.49, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.
/s/ Jorey Chernett 03/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did TOI’s 10% owner report in this Form 4?

TOI’s 10% owner Jorey Chernett reported three open-market purchases of Oncology Institute common stock, totaling 398,985 shares. These trades occurred over several days at weighted average prices between roughly $2.92 and $3.42 per share, increasing his direct ownership stake in the company.

How many Oncology Institute (TOI) shares does Jorey Chernett now own?

After the reported transactions, Jorey Chernett directly owns 10,251,929 shares of Oncology Institute common stock. This figure comes from the post-transaction share totals disclosed for the most recent purchase, reflecting his enlarged position as a disclosed 10% beneficial owner of TOI.

At what prices did the TOI insider buy shares in these transactions?

The Form 4 reports weighted average purchase prices of $2.92, $3.29, and $3.42 per share for the three transactions. Footnotes clarify that each figure is a weighted average across multiple trades executed within specified intraday ranges around those prices, rounded to the nearest cent.

Were TOI insider Jorey Chernett’s transactions open-market purchases or option exercises?

All three TOI transactions are coded “P,” indicating open-market or private purchases of common stock rather than option exercises or derivative conversions. The derivative section of the filing shows no derivative transactions, so these trades directly increase his common share holdings.

How many TOI shares did the insider buy on each reported date?

Oncology Institute’s Form 4 shows Jorey Chernett bought 263,000 shares on March 13, 60,985 shares on March 16, and 75,000 shares on March 17. Together these open-market purchases total 398,985 shares of TOI common stock across the three consecutive trading days.
The Oncology Institute Inc

NASDAQ:TOI

View TOI Stock Overview

TOI Rankings

TOI Latest News

TOI Latest SEC Filings

TOI Stock Data

337.04M
84.09M
Medical Care Facilities
Services-offices & Clinics of Doctors of Medicine
Link
United States
CERRITOS